+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Coronary Artery Disease

  • ID: 4775146
  • Report
  • 40 pages
  • Datamonitor Healthcare
1 of 2
This Market Spotlight report covers the coronary artery disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, patent information, 10-year disease prevalence and incidence forecasts and licensing and acquisition deals.

Key Takeaways
  • The author estimates that in 2017, there were approximately 327.9 million prevalent cases of coronary artery disease worldwide, and forecaststhat number to increase to 365.9 million prevalent cases by 2026.
  • Coronary artery disease has a male predominance. Globally, the author estimates that in 2017, 58.65% of cases aged 15 years and over were male.
  • The author estimates that in 2017, there were approximately 9.5 million incident cases of acute coronary syndrome worldwide, and forecaststhat number to increase to 10.7 million incident cases by 2026.
  • Acute coronary syndrome has a male predominance. Globally, the author estimates that in 2017, 63.78% of cases aged 25 years and over were male.
  • Symplmed’s Aceon, Grifols’s Albutein, Pfizer’s Caduet, and Johnson & Johnson’s Xarelto are the only marketed drugs available for coronary artery disease. These drugs are administered via the oral and intravenous routes.
  • The majority of industry-sponsored drugs in active clinical development for coronary artery disease are in Phase II. Therapies in mid-to-late-stage development for coronary artery disease focus on a wide variety of targets. These drugs are administered via the oral, intravenous, and percutaneous catheter/injection routes.
  • The overall likelihood of approval of a Phase I cardiovascular disease asset is 8.3%, and the average probability a drug advances from Phase III is 54.1%. Drugs, on average, take 9.7 years from Phase I to approval in the overall cardiovascular space.
  • There were 11 licensing and asset acquisition deals involving coronary artery disease drugs during 2014–18. The definitive license agreement in 2017 between Lantheus and GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent, for $65m, was the largest deal.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for coronary artery disease have been in the late phases of development, with 53% of trials in Phase III–IV, and 47% in Phase I–II.
  • The US has a substantial lead in the number of coronary artery disease clinical trials globally. The UK and Germany lead the major EU markets, while China has the top spot in Asia.
  • Clinical trial activity in the coronary artery disease space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for coronary artery disease, with 95 trials.
  • Pfizer leads industry sponsors with the highest number of clinical trials for coronary artery disease.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Medical management
Medical procedures and surgery
Cardiac rehabilitation

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
Xarelto for Coronary Artery Disease (August 27, 2018)
Xarelto for Coronary Artery Disease (August 27, 2017)

KEY REGULATORY EVENTS
FDA Lowers Barrier To Market Penetration For Abiomed's Impella With Expanded Indication

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
Aspire Health Licenses Rights To Hemostemix's ACP01

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY
Prescription information

APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of coronary artery disease, 2017–26
Figure 2: Trends in incident cases of acute coronary syndrome, 2017–26
Figure 3: Overview of pipeline drugs for coronary artery disease in the US
Figure 4: Pipeline drugs for coronary artery disease, by company
Figure 5: Pipeline drugs for coronary artery disease, by drug type
Figure 6: Pipeline drugs for coronary artery disease, by classification
Figure 7: Xarelto for Coronary Artery Disease (August 27, 2018): Phase III - COMMANDER-HF (HF/CAD)
Figure 8: Xarelto for Coronary Artery Disease (August 27, 2017): Phase III - COMPASS
Figure 9: Probability of success in the coronary artery disease pipeline
Figure 10: Licensing and asset acquisition deals in coronary artery disease, 2014–18
Figure 11: Parent patents in coronary artery disease
Figure 12: Clinical trials in coronary artery disease
Figure 13: Top 10 drugs for clinical trials in coronary artery disease
Figure 14: Top 10 companies for clinical trials in coronary artery disease
Figure 15: Trial locations in coronary artery disease
Figure 16: Coronary artery disease trials status
Figure 17: Coronary artery disease trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of coronary artery disease, 2017–26
Table 2: Prevalent cases of coronary artery disease, by gender, 2017
Table 3: Incident cases of acute coronary syndrome, 2017–26
Table 4: Incident cases of acute coronary syndrome, by gender, 2017
Table 5: Marketed drugs for coronary artery disease
Table 6: Pipeline drugs for coronary artery disease in the US
Table 7: Xarelto for Coronary Artery Disease (August 27, 2018)
Table 8: Xarelto for Coronary Artery Disease (August 27, 2017)
Table 9: Historical global sales, by drugs ($m), 2013–17
Table 10: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll